Gilead Sciences (NASDAQ:GILD) Price Target Raised to $100.00

Gilead Sciences (NASDAQ:GILD) had its price target raised by Royal Bank Of Canada from $98.00 to $100.00 in a research note released on Wednesday,MarketScreener reports. They currently have a sector perform rating on the biopharmaceutical company’s stock.

Other equities analysts also recently issued research reports about the company. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price on the stock in a research report on Friday, July 25th. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price on the stock in a research note on Tuesday, August 19th. Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research note on Saturday, September 27th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $118.08.

Gilead Sciences Stock Performance

GILD opened at $117.18 on Wednesday. The firm’s fifty day simple moving average is $114.65 and its two-hundred day simple moving average is $110.25. Gilead Sciences has a 52-week low of $84.17 and a 52-week high of $121.83. The company has a market cap of $145.40 billion, a price-to-earnings ratio of 23.34, a PEG ratio of 0.79 and a beta of 0.34. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts anticipate that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.7%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio is presently 62.95%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the sale, the insider owned 113,193 shares in the company, valued at $12,855,329.01. The trade was a 2.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the transaction, the chief financial officer owned 159,555 shares of the company’s stock, valued at approximately $18,120,661.35. This represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock valued at $9,402,130 over the last quarter. 0.27% of the stock is owned by insiders.

Hedge Funds Weigh In On Gilead Sciences

Several large investors have recently made changes to their positions in GILD. Brighton Jones LLC grew its stake in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after buying an additional 2,450 shares in the last quarter. Bison Wealth LLC purchased a new position in Gilead Sciences during the 4th quarter valued at about $215,000. GAMMA Investing LLC grew its position in Gilead Sciences by 24.9% in the 1st quarter. GAMMA Investing LLC now owns 22,760 shares of the biopharmaceutical company’s stock valued at $2,550,000 after acquiring an additional 4,532 shares in the last quarter. Simplicity Wealth LLC purchased a new stake in Gilead Sciences during the first quarter worth about $483,000. Finally, Accurate Wealth Management LLC lifted its position in shares of Gilead Sciences by 36.4% during the first quarter. Accurate Wealth Management LLC now owns 4,714 shares of the biopharmaceutical company’s stock worth $489,000 after purchasing an additional 1,258 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.